Ecolab Inc. (ECL) Earnings Call Transcripts
Ecolab Inc.'s Latest Earnings Call - Q2 FY2026
Ecolab Inc. reported a strong second quarter for fiscal year 2026, with adjusted EPS growing 11% and organic sales growth accelerating to 5%. Revenue for the quarter was $3.2 billion, slightly above expectations, driven by strong performance across multiple segments, particularly Life Sciences and Global High-Tech. Management raised guidance for the full year, now expecting EPS in the range of $8.05 to $8.25, reflecting a 7% to 10% increase year-over-year, indicating confidence in continued momentum despite external challenges.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $3.2B (beat) |
| Adjusted EPS | $2.15 (beat) |
| Organic Sales Growth | 5% (beat) |
| Life Sciences Growth | 15% (positive) |
| Global High-Tech Growth | 29% (positive) |
| Pricing Strength | 4% (positive) |
Guidance from management
Management expects organic sales growth of 6% to 7% in the second half of 2026, with adjusted operating income margins projected at 19%. The guidance for EPS has been raised to $8.05 to $8.25 for the full year.
What management said
Yes. The only thing, Tim, that I would add is that next year, as you might remember, the Nalco amortization falls off. And so that's also as part of, when you said how do you reconcile that, that we do get the benefit of annualizing the CoolIT amortization, but offset by the Nalco amortization.
Yes. Just more broadly, as Christophe talked about, we will invest ahead of growth in the growth engines, but expect that the CapEx as a company to remain similar to where we're at now for the next couple of years. And we've talked about this for a little while, likely remaining around the 7% in the next couple of years because we are investing ahead for the Global High-Tech business and Life Science. But then as we ...
What analysts pressed on
Analysts expressed concerns regarding the impact of rising commodity costs on margins and questioned the sustainability of volume growth in light of geopolitical disruptions. Additionally, there were inquiries about the integration and growth trajectory of the CoolIT acquisition.
Main topics on the call
- Revenue Growth Acceleration — Ecolab achieved organic sales growth of 5% in Q2 2026, with management stating, "momentum continued to strengthen across the portfolio." This growth was driven by strong performances in Food & Beverage, Life Sciences, an...
- Pricing Strategy — Management noted that pricing strengthened to 4% in Q2 and expects it to reach 5% to 6% in the second half of the year, stating, "this is allowing us to offset the impact of rising commodity costs on our margins and EPS ...
- Life Sciences Performance — Life Sciences segment saw a remarkable 15% growth, attributed to strong share gains in bioprocessing and pharma. Management highlighted that this segment is expected to maintain mid-20% operating income margins, reflecti...
- Global High-Tech Growth — Global High-Tech revenue accelerated to 29%, driven by demand in microelectronics and data centers. Management stated, "Global High-Tech is now our largest growth engine," with expectations of reaching $4 billion in sale...
Read the full Ecolab Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Ecolab Inc.
Ecolab Inc. (ECL) is a publicly listed company in the Chemicals industry, within the Materials sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 91 calls on record spanning February 18, 2020 to July 28, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 91 Ecolab Inc. earnings call transcripts on record, spanning February 18, 2020 to July 28, 2026. Based on this history, Ecolab Inc. reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.